If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...
Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback